Helping Africans Control Pharma Research With Boost From McGill, Gates Foundation

A McGill University parasitology researcher has received a $100,000 grant from the Gates Foundation to help establish locally controlled pharmaceutical-research programs in Botswana and South Africa.

“People are always asking why the pharmaceutical industry doesn’t do very much work on diseases of the poor, like parasitic infections,” said Dr. Timothy Geary, of McGill’s Institute of Parasitology. “There’s a simple answer: they don’t make any money at it, just as road building companies don’t build roads for free in Africa. The real solution to the problem is to develop indigenous capacity. There’s no reason it shouldn’t work, Africans have historically been very good at all kinds of research, for instance, in natural products chemistry.”

Geary, McGill’s Canada Research Chair in Parasite Biotechnology, is an expert in the area of antiparasitic drugs. He points out that over the last couple of decades, drug companies have largely stopped screening chemicals derived naturally from tropical plants or microbes – a major source for antiparasitics – for both economic and political reasons.

“Over the last 15 or 20 years there has been tension between the industrialized north and the developing south over this issue,” he continued. “There was a sense in the south that people from the north were simply looting this resource. We called it bioprospecting; they called it ‘biopiracy,’ which caused obvious problems in negotiating access and contracts.”

Moreover, said Geary, philanthropic attempts to establish a pharmaceutical research base in Africa often fail because they lack the crucial element of sustainability: Donations of expensive high-tech equipment typically do not take long-term maintenance into account, for example.

“African researchers are just as capable as anyone else of utilizing the highest high technology,” he said, “But once the laser goes out or the microprocessor fails, getting a piece of high-tech lab equipment repaired is a real challenge.”

Geary’s program, developed in close concert with colleague Dr. Eliane Ubalijoro of McGill’s Centre for Developing-Area Studies, replaces high-technology screening apparatus with genetically engineered yeast strains and E. coli bacteria. These organisms have been modified to produce proteins normally only found in parasitic worms, making them an ideal laboratory test-bed for potential antiparasitic drugs.

“The very survival of the microbe is dependent on the function of the parasite protein,” Geary explained. “So if a drug is working, it will affect the growth of the organism. This is easy to monitor, because these organisms are extremely well understood. It’s a very robust system.

“This way, instead of shipping the chemicals to the high-throughput, mechanism-based screening processes that drive the pharmaceutical industry, we bring the process to the chemicals. Africans will do the research and own the intellectual property. This creates sustainability: if you can license the products of your screening, you have a revenue stream.”

In the longer term, Geary hopes to assemble chemical collections from various researchers across Africa.

“We are guessing that we need to get around 50,000 novel chemicals that might be of interest to western pharmaceutical companies,” he said. “My belief, coming from the industry, is that if you provide this resource at a reasonable cost, they will subscribe to it.

“The other goal, that’s very important, is that Africans should be leading this program in the very short term, two to three years. I hope to make myself irrelevant.”

###

This release is available in French.

Source: Mark Shainblum

McGill University

U.S. Consumers Place More Importance On Price And Value When Choosing Over-the-Counter Products Compared To Global Consumers

An added sign of a battered U.S. economy, U.S. consumers place more importance on price and value when choosing over-the-counter (OTC) medication compared to global consumers, according to a global online survey conducted by The Nielsen Company in partnership with the Association of the European Self-Medication Industry (AESGP).

Thirty percent of U.S. consumers consider price important when choosing OTC products, while on average, only 17 percent of global consumers do. Only Japanese consumers place more importance on price (33 percent). One quarter of Americans consider whether the product is a good value for money, while on average, 15 percent of global consumers make this a consideration.

“With increasing medical costs and a fragile economy, the U.S. consumer is more price and value centric than ever,” said Matt Dumas, managing director, NielsenHealth. “These findings highlight the rising importance of generic drugs in the U.S. market, which is underscored by low OTC product loyalty scores versus global markets. Branded OTC manufacturers need to ensure they develop and invest in their brands instead of simply focusing on the efficacy of their products in order to vie in such a competitive price-driven environment.”

Nielsen’s research shows that product loyalty is more important in other parts of the world. Twelve percent of U.S. consumers consider whether the product is one that they usually use, while nearly one quarter (23 percent) of global consumers do. And, only seven percent of U.S. consumers consider whether or not the product is recognizable as important, compared to sixteen percent of global consumers.

Tell Me It Works

When choosing OTC medication, U.S. consumers rank the product’s effectiveness, safety and whether or not they have confidence in the product as most important. According to Nielsen’s research, fifty percent of U.S. consumers ranked “I know it works” as an important factor when choosing OTC medication, while four out of ten (42 percent) U.S. consumers cited “I know it is safe” and 35 percent responded that having confidence in the product were important. Least important to U.S. consumers are recognizable products (7 percent), easy to take products (8 percent) and choosing products because it is usually used (12 percent).

“With a highly competitive OTC marketplace in the U.S., a product’s effectiveness is the driving factor behind consumer preference,” said David Parma, global head of Nielsen Consumer Research. “Safety clearly is top of mind, particularly now with the recent intervention by the FDA in prescription and OTC medication. OTC manufacturers need to do a really good job of communicating the safety of their products in light of this.”

Additional Findings

Other key findings include:

- When feeling the first signs of a minor ailment, 60 percent of U.S. consumers usually wait to see if it gets better before taking medicine. Twenty-five percent usually take medicine as soon as they start to feel unwell, while only nine percent always take medicine as soon as they start to feel ill.

- Of those consumers that usually wait to see if they get better or never take medicine, 34 percent respond that the main reason they do not take medicine is because taking medicines can be harmful to your health. Fourteen percent indicate that they do not take medicine because medicines are too expensive.

- When asked what would help them take care of their health and minor ailments, U.S. consumers indicated more advice or support from their doctors (44 percent), clearer information on and in the pack of medicine (36 percent) and more health education (33 percent).

- Forty-nine percent of U.S. consumers strongly agree or agree that more medicines should be available without a prescription from the doctor. Thirty-one percent strongly disagree or disagree, while thirty-one percent don’t have an opinion or don’t know.

About the Survey

The Nielsen Global Online Consumer Survey, conducted by Nielsen Consumer Research, was conducted in April and May 2008 among 28,253 Internet users in 51 markets in Europe, Asia Pacific, North America and the Middle East. The largest half-yearly survey of its kind, the Nielsen Global Online Consumer Confidence and Opinion Survey provides insight into current confidence levels, spending habits/intentions and the major concerns of consumers across the globe.

About The Nielsen Company

The Nielsen Company is a global information and media company with leading marketing and consumer information, television and other media measurement, online intelligence, mobile measurement, trade shows and business publications (Billboard, The Hollywood Reporter, Adweek). The privately held company is active in more than 100 countries, with headquarters in New York, USA. For more information, please visit, nielsen.

Source
Jennifer Frighetto
The Nielsen Company

Asthma UK Northern Ireland Swine Flu Advice

Following the latest figures for deaths from swine flu from the Public Health Agency Asthma UK Northern Ireland is urging parents of children with asthma to have their children vaccinated.

According to Public Health Agency, 17 people have died of swine flu in Northern Ireland this season. Joan O’Hagan, Director of Asthma UK Northern Ireland said: ‘We urge the 182,000 people with asthma in Northern Ireland to have the swine flu vaccine. Although swine flu is mild in most cases, people with asthma are at risk of serious breathing complications such as pneumonia if they do develop the illness.’

The free seasonal flu vaccine includes protection against swine flu. People with asthma should be invited to their GP practice to receive the vaccine. If this has not happened, they are advised to contact their GP practice to schedule a vaccination.

The vaccine should also be available from most pharmacies. However, some high-street pharmacy chains, such as Boots, Sainsbury’s and Tesco, will not provide the vaccine to anyone under 16. Parents of children with asthma are advised to check with their local pharmacies.

Parents of children with asthma should take further precautions, including ensuring that their children attend a twice-yearly asthma review and have an up-to-date Personal Asthma Action Plan, which gives information on what to do if their asthma gets worse. Parents should also find out if their child’s school has an asthma policy in place.

Children and teachers suffering from flu have been urged to stay at home. Swine flu is spread by droplets from talking, coughing or sneezing and contact with those droplets on surfaces. Parents of children with asthma should make sure their children understand the importance of coughing or sneezing into a tissue, which they can then put in the bin, and then washing their hands thoroughly.

Source:

Asthma UK

Nationwide Aging Study To Be Led By Bloomberg School Of Public Health

Researchers at the Johns Hopkins Bloomberg School of Public Health have been selected to lead a new national survey of older Americans to understand patterns of disability and aging. The National Institute on Aging (NIA), part of the National Institutes of Health, is expected to award approximately $24 million over the next five years to develop and implement the new survey. The study will include investigators from the University of Medicine & Dentistry of New Jersey, Brown University, Columbia University, the Medical College of Wisconsin, the Urban Institute, the University of Iowa, Syracuse University and the survey research firm, Westat.

“Our aim is to provide scientific evidence that can help in reducing disability and improving the daily lives of older people,” said Judy Kasper, PhD, principal investigator of the study and professor in the Bloomberg School’s Department of Health Policy and Management. “We will assemble a rich database of information that will allow researchers to study how people’s ability to function independently changes over time, as well as examine the factors that influence those changes, such as social environment and medical care.”

The study also is designed to provide trend data on disability comparable to the 1982? National Long-Term Care Survey that showed a major decline in disability among people 65 and older, beginning around 1984.

The first phase of the study will include 12,000 Medicare enrollees, ages 65 and older. The participants will be surveyed annually with new participants being added to the study every five years. New survey tools will be developed to measure and examine trends in late-life independence and wellbeing, how these trends differ by race and socioeconomic status, and the family and societal consequences of disability.

“New national surveys are rare. Johns Hopkins is privileged to have this opportunity to serve our nation by leading a team that can discover how best to reduce the human and financial costs of age-related disability,” said Scott Zeger, PhD, Vice Provost for Research for Johns Hopkins University.

“The trend in declining disability among older Americans is an important indicator that shows that we can improve health and independence as we age,” said Richard Suzman, PhD, director of the Division of Behavioral and Social Research at the NIA. “We hope that this study will play a critical role in maintaining or accelerating this trend as we address the challenges of our aging population.” Georgeanne E. Patmios serves as NIA’s program official on the project.

###

Source: Tim Parsons

Johns Hopkins University Bloomberg School of Public Health

Recommendation By Researchers To Strengthen Restrictions On Off-Label Promotion By Pharmaceutical Companies

Researchers are asking for tougher penalties and fines for pharmaceutical companies that market drugs for “off label” promotion, according to a study published in the October 28 issue of the open access journal PLoS Medicine.

New regulations are needed to address this practice, say Adriane Fugh-Berman, M.D., an associate professor in the GUMC Department of Physiology and Biophysics, and Douglas Melnick, M.D., a preventive medicine physician in the Los Angeles County Department of Public Health. In the article, Fugh-Berman and Melnick address public health issues associated with off-label promotion and marketing.

Both authors have extensive experience with the pharmaceutical industry. Melnick once worked in as a physician in industry medical affairs, which supported pharmaceutical marketing efforts. Fugh-Berman is the principal investigator of PharmedOut, a project to educate physicians about the influence that pharmaceutical companies have on drug prescribing.

They argue that “states and other jurisdictions have a duty to protect the health of the public. Allowing off-label promotion of drugs for untested, unproven benefits maximizes industry profits at the expense of public health.”

In their study, they detail the ways that the pharmaceutical industry uses marketing to encourage “the unmonitored, potentially dangerous use of drugs by patients for whom risks and benefits are unknown.”

The researchers are careful to point out that off-label use is sometimes necessary and is subject to a physicians’ best judgment.

“While off-label use is sometimes necessary… valuable off-label uses should be discussed by unbiased researchers in bona fide medical journals. Promising therapies should be tested in clinical trials. Truly useful off-label benefits of drugs will not remain a secret.”

Marketing of off-label use of drugs is widespread

Once a drug is approved for at least one indication, it may legally be prescribed off-label for a different condition, a different population, or in a different dose than what the drug is approved for. However, off-label uses have not been subject to the testing and review that is a precondition for marketing approval, the authors say.

Off-label prescription of a drug is generally legal, and is sometimes unavoidable, especially because drugs are often not tested in children or in pregnant women. And while some off-label use is very beneficial, the authors say, benefit is unknown for most off-label uses because the drugs have not been studied for those conditions.

What is usually illegal, and what the authors highlight in their paper, is promotion of off-label uses by a drug manufacturer. But there are ways the industry encourages these uses anyway, the authors say. Among the strategies are:
Seeking federal approval for a narrow use of a new drug in order to speed a drug to market because a company anticipates extensive off-label use. “In other words, a drug may be approved for a decoy indication while an extensive off-label campaign is not disclosed to regulators,” the authors say.

Once a drug is approved for a decoy indication, labeled and off-label promotion may occur concurrently through journal advertising, direct mail, publication of “case studies”, presentation of posters and abstracts at scientific meetings, and through “word-of-mouth” or “buzz” marketing by nationally known, influential academic physicians. Pharmaceutical marketing has distorted the discourse on off-label uses and encouraged the unmonitored, potentially dangerous use of drugs by patients for whom risks and benefits are unknown, the researchers say.

They suggest that restrictions to off-label promotion of drugs should be strengthened and that “companies that engage in off-label promotion should be heavily fined and their future marketing practices subject to increased scrutiny by regulatory agencies.”

###

PharmedOut is funded through the Attorney General Consumer and Prescriber Education grant program, created as part of a 2004 settlement between Warner-Lambert, a division of Pfizer, Inc., and the Attorneys General of 50 States and the District of Columbia, to settle allegations that Warner-Lambert conducted an unlawful marketing campaign for the drug Neurontin® (gabapentin) that violated state consumer protection laws. Fugh-Berman has been a paid expert witness on the plaintiff’s side in litigation regarding pharmaceutical marketing practices. Melnick reports no disclosures.

This study received no specific funding.

About Georgetown University Medical Center

Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through our partnership with MedStar Health). Our mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis — or “care of the whole person.” The Medical Center includes the School of Medicine and the School of Nursing and Health Studies, both nationally ranked, the world-renowned Lombardi Comprehensive Cancer Center and the Biomedical Graduate Research Organization (BGRO), home to 60 percent of the university’s sponsored research funding.

Click here to access the published paper.

Source: Karen Mallet

Georgetown University Medical Center

View drug information on Neurontin.

Program Created To Calculate Body Shape

Imagine you are a police detective trying to identify a suspect wearing a trench coat, baggy pants and a baseball cap pulled low. Or imagine you are a fashion industry executive who wants to market virtual clothing that customers of all shapes and sizes can try online before they purchase. Perhaps you want to create the next generation of “Guitar Hero” in which the user, not some character, is pumping out the licks. The main obstacle to these and other pursuits is creating a realistic, 3-D body shape -especially when the figure is clothed or obscured.

“If you see a person wearing clothing, can the computer figure out what they look like underneath?” asked Michael Black, professor of the computer science at Brown.

Black and graduate student Alexandru Balan believe they have figured out how that can be done. The researchers have created a computer program that can accurately map the human body’s shape from digital images or video. This is an advance from current body scanning technology, which requires people to stand still without clothing in order to produce a 3-D model of the body.

With the new 3-D body-shape model, the scientists can determine a person’s gender and calculate an individual’s waist size, chest size, height, weight and other features.

Black and Balan debuted their findings this month at the European Conference on Computer Vision in Marseilles, France. Their paper is one of fewer than 5 percent of submitted manuscripts chosen for oral presentation at the prestigious international gathering.

A simulation of the new technology can be seen here: cs.brown.edu/~alb/scapeClothing/.

The potential applications are broad. Besides forensics and fashion, Black and Balan’s research could benefit the film industry. Currently, actors must wear tight-fitting suits covered with reflective markers to have their motion captured. The new approach could capture both the actors’ shape and motion, while doing away with the markers and suits.

In sports medicine, doctors would be able to use accurate, computerized models of athletes’ bodies to better identify susceptibility to injury. In the gaming world, it could mean the next generation of interactive technology. Instead of acting through a character, a camera could track the user, create a 3-D representation of that person’s body and insert the user into the video game.

Brown University has filed two provisional patents covering the research and its potential commercial applications.

The key insight for Black and Balan was when they learned they could divine clues about a person’s shape even with clothing. They created a computerized body model from 2,400 detailed laser range scans of men and women in minimal clothing. They found that by combining information from a person in multiple poses, the computer was able to infer the gender of the person and the 3-D body shape. They further refined the model by incorporating the computer’s detection of skin in the images.

“As I move, my clothes become loose or tight on different parts of my body,” Black said. “Each pose gives different constraints on the underlying body shape, so while a person’s body pose may change, his or her true shape remains the same. By analyzing the body in different poses, we can better guess that person’s true shape.”

The researchers stress the technique is not invasive; it does not use X-rays, nor does it actually see through clothing. The software makes an intelligent guess about the person’s exact body shape.

###

The Office of Naval Research, the Rhode Island Economic Development Corp. and the Intel Corp. funded the research.

Source: Richard Lewis

Brown University

Spread Of Flu-Like Symptoms Halved By Masks, Hand Washing

Wearing masks and using alcohol-based hand sanitizers may prevent the spread of flu symptoms by as much as 50 percent, a landmark new study suggests.

In a first-of-its-kind look at the efficacy of non-pharmaceutical interventions in controlling the spread of the flu virus in a community setting, researchers at the University of Michigan School of Public Health studied more than 1,000 student subjects from seven U-M residence halls during last year’s flu season.

“The first-year results (2006-2007) indicate that mask use and alcohol-based hand sanitizer help reduce influenza- like illness rates, ranging from 10 to 50 percent over the study period,” said Allison Aiello, co-principal investigator and assistant professor of epidemiology at the U-M SPH. Dr. Arnold Monto, professor of epidemiology, is also a principal investigator of the study.

Aiello stressed the first year of the two-year project, called M-Flu, was a very mild flu season and only a few cases were positive for flu, so results should be interpreted cautiously. Ongoing studies will test for other viruses that may be responsible for the influenza-like illness symptoms observed, she said.

“Nevertheless, these initial results are encouraging since masks and hand hygiene may be effective for preventing a range of respiratory illnesses,” Aiello said.

The findings, “Mask Use Reduces Seasonal Influenza-like Illness In The Community Setting,” was presented Sunday at The Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America annual meeting in Washington, D.C.

At the start of flu season in the last two years, participants were randomly assigned to six weeks of wearing a standard medical procedure mask alone, mask use and hand sanitizer use, or a control group with no intervention. Researchers followed students for incidence of influenza like illness symptoms, defined as cough with at least one other characteristic symptom such as fever, chills or body aches, Monto said.

From the third week on, both the mask only and mask/hand sanitizer interventions showed a significant or nearly significant reduction in the rate of influenza-like illness symptoms in comparison to the control group. The observed reduction in rate of flu-like symptoms remained even after adjusting for gender, race/ethnicity, hand washing practices, sleep quality, and flu vaccination.

Non-pharmaceutical interventions such as hand washing and masks—especially in a pandemic flu outbreak—are critical to study because pharmaceutical interventions such as vaccinations and antivirals may not be available in sufficient quantity for preventing and controlling pandemic influenza outbreaks.

In February 2007, the Centers for Disease Control and Prevention and the U.S. Department of Health and Human Services in collaboration with other federal agencies, education, businesses, healthcare and private sectors developed an interim planning guide on the use of Non-Pharmaceutical Interventions (NPIs) to mitigate an influenza pandemic.

The measures include voluntary home quarantine, isolation and treatment of cases, social distancing, personal protection such as face masks and hand hygiene, and school dismissal.

“Although a few of these measures can be evaluated during seasonal influenza outbreaks, many are difficult or impossible to evaluate in advance of a pandemic,” Monto said. “However, use of face masks and hand hygiene interventions can be evaluated now, during seasonal influenza outbreaks, which can provide concrete evidence for decision makers.”

Further studies are needed to confirm whether mask use may be an effective means of reducing influenza in shared living settings. Since it was not possible to blind subjects, knowledge of the intervention may have influenced influenza-like symptom reporting and therefore the results of this study should be interpreted with caution, Aiello said.

“During year two of the study (2007-2008) a major outbreak of influenza took place,” Aiello said. “Forthcoming studies will examine whether results observed during this more severe outbreak mirror those observed during the milder year one influenza season. Influenza virus identification will also be examined as an additional outcome.”

###

The M-Flu study is a collaboration between SPH, U-M Housing, and University of Michigan Heath Services. The study was funded by Centers for Disease Control and Prevention.

Co-authors include: Genevra Murray, PhD; Rebecca Coulborn, BS; Anne-Michelle Noone, all of the U-M SPH Department of Epidemiology.

For information about M-Flu, including video, news clips, FAQs, visit: sph.umich.edu/mflu/

For information about the U-M SPH: sph.umich.edu/

For information about Aiello: click here

For information about Monto: click here

The University of Michigan School of Public Health has been working to promote health and prevent disease since 1941, and is consistently ranked among the top five public health schools in the nation. Faculty and students in the school’s five academic departments and dozens of collaborative centers and initiatives are forging new solutions to the complex health challenges of today, including chronic disease, health care quality and finance, emerging genetic technologies, climate change, socioeconomic inequalities and their impact on health, infectious disease, and the globalization of health.

Source: Laura Bailey

University of Michigan

Editorial Addresses ‘Scrimping’ On Medical Care

Recent surveys have found that, as a result of the current economic downturn, “many Americans are skimping on medications, physician visits and preventive screening in order to pay other household bills,” and the trend “could be dangerous to their health and costly for the economy if more Americans lose work time or end up in the hospital,” a New York Times editorial states (New York Times, 10/26).

The Times cites the latest tracking poll by the Kaiser Family Foundation, finding that one in three U.S. residents say their family has had problems paying medical bills in the past year, and nearly half say someone in their family has skipped or delayed medical care because of the cost. Other surveys conducted recently by “insurance groups and health care organizations have had similar findings,” the editorial states. In addition, an analysis conducted recently by IMS Health found that U.S. prescription drug sales decreased in the second quarter, the first time that sales have not increased in at least the past 12 years, according to the editorial.

“The scrimping underscores the need to provide health insurance with affordable premiums and copayments for all and to bring down medical costs,” the editorial states, adding, “In tough times, no one should have to forgo needed health care” (New York Times, 10/26).

Reprinted with kind permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation.

© 2008 Advisory Board Company and Kaiser Family Foundation.В  All rights reserved.

Alive And Working: How Access To Newer Drugs Keeps Americans Off Disability Roles

Today, October 28, 2008, the Center for Medical Progress at the Manhattan Institute, released a new report authored by Columbia University professor Frank Lichtenberg, entitled “Alive and Working: How access to newer drugs keeps Americans off disability roles.” In this study, Dr. Lichtenberg demonstrated that the use of newer prescription drugs, one type of medical innovation, has helped reduce the growth in U.S. disability rates.

By examining patterns in drug prescription in 49 of the 50 states from the period of 1995-2004, Dr. Lichtenberg determined that a state’s average drug vintage, or how recently the drugs active ingredients was approved by the FDA, was a significant factor in determining the size of disability rolls. In the states where the average drug vintage was more recent, the disability rates rose more slowly.

Overall impact of new drugs on disability rates and expenditure

- The disability rate would have been 30% higher
- 418,000 more Americans would have been disability recipients
- The cost of Social Security disability payments would have been $4.5 billion dollars higher

Impact on States

- California, Idaho, Rhode Island, Maryland, and Connecticut had the lowest increases in number of disability recipients

- Oklahoma, Alabama, Texas, Louisiana, and West Virginia, had the largest increases ,75% greater than the first five states, in number of disability recipients

As policymakers grapple with falling tax receipts and severe budget constraints, they must search for ways to reduce program expenditures-or at least, to slow their rate of growth. In this regard, measures to keep working-age Americans off disability rolls-for instance, through access to improved medical innovations-should be particularly welcome.

Importance of findings

- Access to newer drugs will keep more Americans off disability rolls and allow them to remain wage earners and taxpayers
- States should consider how keeping their citizens in better health today can help offset future safety net spending

Frank Lichtenberg currently serves as the Courtney C. Brown Professor of Business at the Columbia University Graduate School of Business as well as a research associate of the National Bureau of Economic Research. His work has focused on how new technologies affect the productivity of companies, industries, and nations.

The Manhattan Institute, a 501(c)(3), is a think tank whose mission is to develop and disseminate new ideas that foster greater economic choice and individual responsibility.

The Manhattan Institute

Newspapers Examine Effect Of Economic Downturn On Prospects For Candidates’ Health Proposals

The current economic downturn and the recent enactment of a $700 billion bailout for Wall Street firms could have implications for the next president’s health care proposal, as well as other plans, the Chicago Tribune reports. According to the Tribune, “resources will be sharply constrained” when the next president takes office, and efforts to address the “economy’s overall health will be the overwhelming task of the new president and Congress, drowning out most other priorities.”

The health care proposal announced by Democratic presidential nominee Sen. Barack Obama (Ill.) is unlikely to pass in Congress next year, and the plan announced by Republican presidential nominee Sen. John McCain (Ariz.) is “even less likely to pass because it relies on eliminating a popular tax break for employer-provided health care, which would be anathema to a Democratic Congress and stir strong opposition from business and labor groups,” the Tribune reports (Dorning, Chicago Tribune, 10/25). “Congress is likely to look at more limited and incremental moves to expand coverage,” such as an expansion of SCHIP, according to the Wall Street Journal (Wilde Mathews, Wall Street Journal, 10/27).

James Pfiffner, a public policy professor at George Mason University, said, “Both of them have promised many policy initiatives,” adding, “But it’s highly unlikely either one of them could get a lot of important legislation through Congress in the first year, particularly when Congress is so polarized” (Chicago Tribune, 10/25).

George Edwards, a scholar of the presidency and a political scientist at Texas A&M University, said that McCain “has very poor prospects,” as his “approach to health care probably would not be the one the Democrats would pick up on” (Thomma, McClatchy/Miami Herald, 10/26).

Employers Raise Concerns About Obama Proposal
Some employers have raised concerns about a provision in the Obama health care proposal that would require them to offer health insurance to employees or pay a percentage of their payrolls into a federal fund to provide coverage, with an exemption for small businesses, the New York Times reports. According to the New York Times, although Obama has not specified the amount of the percentage, “economists believe he might require large and medium companies to contribute as much as 6% of their payrolls.” In addition, Obama has not specified a definition for small businesses.

David Cutler, a Harvard University economist and adviser to Obama, said, “We made a decision even before the plan was rolled out not to decide” on either issue, adding, “It’s not that there’s a decision out there that we’re not telling. It’s literally that we’ve decided not to decide.”

The decision “may be smart politics,” but “it makes business groups nervous that Mr. Obama might impose an unmanageable burden” and that, “any time his health plan faces a shortfall, businesses will be asked to up their ante,” according to the New York Times.

Meanwhile, employers also “have concerns that Mr. McCain’s plan to change the tax treatment of health benefits would erode employer-sponsored insurance,” the New York Times reports (Sack, New York Times, 10/27).

Additional Developments
Summaries of several other recent developments related to health care issues in the presidential election appear belowtholic Healthcare West: The Chronicle on Sunday published an interview with Catholic Healthcare West CEO Lloyd Dean, who said that health care will become a priority for Congress after the economic downturn ends (San Francisco Chronicle, 10/26).

Health care as election issue: The economy has surpassed both health care and the wars in Iraq and Afghanistan as the most important issue to voters in the presidential election, the Newark Star-Ledger reports (Mueller, Newark Star-Ledger, 10/26).

McCain proposal: The AP/Seattle Times on Friday examined the McCain health care proposal, which would result in a “dramatic shift in how millions of people get health insurance coverage” (Freking, AP/Seattle Times, 10/24).

Prospect of Democratic Congress, president: Democrats have begun to outline an agenda for next year that includes “overhauling the health care system” and an expansion of SCHIP, as they have become “increasingly confident” that Obama will win the presidential election and that they will increase their majorities in the House and Senate, the Washington Post reports (Murray, Washington Post, 10/26). According to the New York Times, although Democrats have controlled Congress for the past two years, they have a “pent-up agenda on health care” and other issues on which they “clashed” with President Bush (Hulse/Herszenhorn, New York Times, 10/26).

Editorials
Several newspapers recently published editorials that addressed issues related to health care in the presidential election. Summaries appear below.Financial Times: “The challenges facing the next president will be extraordinary,” and “we hope that Mr. Obama gets the job,” in part because of his proposal for “comprehensive health reform,” a Financial Times editorial states. According to the editorial, the proposal would “achieve nearly universal insurance without the mandates of rival schemes: characteristically, it combines a far-sighted goal with moderation in the method.” The McCain health care proposal “would contain costs better — but is too timid and would widen coverage much less,” the editorial states (Financial Times, 10/27).

Seattle Post-Intelligencer: U.S. residents “need to use the stresses” caused by the recent economic downturn to “reinvigorate public discussion about moving toward more secure health care for all.” While “neither Sen. John McCain or Sen. Barack Obama is offering support for the single-payer system we would like,” the editorial states, “Obama’s ideas offer more to build on.” The editorial adds, “neither candidate is likely to duck the mounting crisis the way President Bush has” (Seattle Post-Intelligencer, 10/26).

St. Petersburg Times: Obama has “qualities to unite this country and the vision to lead it in a new direction” on health care and other issues, and U.S. voters should elect him president, a St. Petersburg Times editorial states. According to the editorial, the Obama proposal “for expanding health care with a blend of public and private coverage stands up well to scrutiny,” and the McCain health care “proposal costs too much to accomplish too little” (St. Petersburg Times, 10/26).

Wall Street Journal: Recent criticisms from the Obama campaign about a McCain proposal to replace an income tax break for employees who receive health insurance from employers with a refundable tax credit for the purchase of private coverage “are especially cynical because his own health care advisers support plans much like Mr. McCain’s,” or “at least they did before joining up with Obama,” a Journal editorial states. The editorial cites an article published in the journal Democracy in 2006 in which Jason Furman, economic policy adviser to Obama, wrote, “The fact that the tax subsidy … is better than nothing is a feeble excuse for resisting any changes to the status quo.” In addition, the editorial states, David Cutler, a professor of economics at Harvard University and an adviser to Obama, in a book published in 2004 wrote, “Health insurance is not something that is made better by tying it to employment” (Wall Street Journal, 10/25).

USA Today: Both the Obama and McCain health care proposals “include worthy ideas,” but “they read too much like summations of party orthodoxy,” a USA Today editorial states. “Ultimately, the best health care plan might combine elements of both McCain’s market-based reforms with mandates to make sure that everyone has access to coverage,” the editorial states. “Given how contentious the campaign has been, that might seem far-fetched,” but “Sen. Ron Wyden (D-Ore.) has a plan (S 334) to do just that,” according to the editorial. “Even if Democrats pad their congressional majorities on Nov. 4, many of the tough issues that this nation faces won’t be solved without bipartisanship,” and health care reform “is no exception,” the editorial states (USA Today, 10/27).

Opinion Pieces
Several newspapers recently published opinion pieces that addressed issues related to health care in the presidential election. Summaries appear below.John Wasik, Bloomberg: Both presidential candidates could help alleviate the U.S.’s current financial situation by helping to increase access to “affordable, portable and universal health care,” according to Bloomberg columnist Wasik. Wasik writes that health care costs are “punishing” to small businesses, noting that research from the Kaiser Family Foundation and the Health Research and Educational Trust has found health insurance premiums have more than doubled since 1999 while inflation has risen 29%. As a result, only about half of small businesses provide health coverage to employees. According to Wasik, “If more people didn’t feel shackled to their large employer for their group health plan, even more jobs would be created as workers could take more risks to start their own businesses” (Wasik, Bloomberg, 10/27).

Jim Blasingame, Memphis Commercial Appeal: “McCain’s health insurance proposal is very similar to” the Small Business Health Plans bill (S 2818) before Congress that would allow small companies to purchase insurance across state lines, writes Blasingame, host of “The Small Business Advocate Show” and Commercial Appeal columnist. He continues, “Obama’s plan is universal health care in reform clothing and the opposite of what small businesses need because it would restrict their health care insurance options” (Blasingame, Memphis Commercial Appeal, 10/27).

Bob Herbert, New York Times: Although few “Americans have noticed,” many U.S. hospitals “are in serious, even dire, financial trouble” and the “current economic downturn” coupled with an anticipated increase in uninsured U.S. residents “will only worsen what is already a crisis,” New York Times columnist Herbert writes. He writes that the “temptation” of the next president “will be to delay bold action on these fronts until the overall economic situation improves,” but adds, “That is the kind of mistake … that opens the door to additional crises.” Herbert writes, “Most important, of course, is a revamping (in a sane way) of the health insurance system” (Herbert, New York Times, 10/25).

Dan Thomasson, Seattle Post-Intelligencer: “About the only thing one can agree on when examining the [health care] promises of Barack Obama and John McCain is that both would cost more money than this country can afford at a time when headlines are proclaiming that many financially hard-pressed Americans are even cutting down on their medical prescriptions to save money,” writes Post-Intelligencer columnist Thomasson. He continues, “In the current economic climate, it is irresponsible for any candidate to make promises that he must know he will have difficulty fulfilling.” Thomasson concludes, “The last thing Americans seem to want to hear about health care is the truth. So neither of the two candidates is willing to tell it or even to admit that their own numbers and solutions are anything but practical” (Thomasson, Seattle Post-Intelligencer, 10/24).

Peter Bray, Slate: “McCain’s health care page has been desperately revised,” with the details of his plan having been “shuttled off elsewhere,” making the page now “pretty much all about his opponent,” Versionista co-founder Bray writes in a Slate opinion piece. “In short, on health care, McCain is backed into a corner,” Bray writes, adding, “The McCain camp now defines its health care plan in relation to Obama’s attacks.” According to Bray, “The assumption is that the public knows more about Obama’s attacks on the plan than about the plan itself” (Bray, Slate, 10/24).

Robert Carroll, Wall Street Journal: McCain’s health insurance tax credit plan “is highly progressive and will provide a powerful incentive for people to purchase health insurance,” Carroll, vice president for economic policy at the Tax Foundation and former deputy assistant secretary for tax analysis at the Department of Treasury, writes in a Journal opinion piece. Carroll writes that the “employer-based system itself is eroding,” adding that eliminating the income-tax exclusion for health benefits “should reduce private health care spending,” which also should “put downward pressure on the growth of Medicare and Medicaid costs. Carroll concludes, “Thus, by removing the tax bias for more generous coverage, the McCain health credit also has the potential to provide important dividends to the entitlement problem down the road” (Carroll, Wall Street Journal, 10/27).

Scott Atlas, Washington Times: “Beware the superficial illusion of moderation — Mr. Obama’s [health care] plan is filled with fantasies about costs, new government mandates and bureaucracies, and in the end, taxes and faith in big government that necessarily will be far greater and broader than his campaign admits, or perhaps worse yet, fails to understand,” Atlas, a senior fellow at the Hoover Institution and a professor at the Stanford School of Medicine, writes in a Washington Times opinion piece. He continues, “John McCain empowers the individual, not the government, by putting control of the health care dollar in the hands of Americans, so they can make value-based purchases of health insurance they actually want, rather than insurance they are forced to buy” (Atlas, Washington Times, 10/26).

Kansas Gov. Kathleen Sebelius (D), Wichita Eagle: “It is a priority for me to see real health care reform in this country,” and “I am working to elect a president who won’t veto health insurance for children, who won’t tax the health benefits offered by employers and who won’t deregulate the health insurance industry the way he deregulated our banking industry,” Sebelius writes in an Eagle opinion piece, in response to an Eagle editorial’s accusations that she has been “working too hard” on behalf of Obama (Sebelius, Wichita Eagle, 10/26).

Broadcast Coverage

C-SPAN’s “Washington Journal” on Friday included a discussion with Marilyn Weber Serafini, an economics correspondent for National Journal, about the positions and records of Obama and McCain on the issues of the uninsured, consumer impact and employer-sponsored health insurance. The segment is the eighth in a 10-part series on the presidential candidates (“Washington Journal,” C-SPAN, 10/24).

Reprinted with kind permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation.

© 2008 Advisory Board Company and Kaiser Family Foundation.В  All rights reserved.


Buy Amiodarone without Prescription Buy Amlodipine without Prescription Buy Atorvastatin without Prescription Buy Avalide without Prescription Buy Azor without Prescription Buy Benazepril without Prescription Buy Bisoprolol without Prescription Buy Caduet without Prescription Buy Capoten without Prescription Buy Carvedilol without Prescription Buy Cilostazol without Prescription Buy Clonidine without Prescription Buy Clopidogrel without Prescription Buy Demadex without Prescription Buy Digoxin without Prescription Buy Diltiazem HCL without Prescription Buy Doxazosin Mesylate without Prescription Buy Enalapril without Prescription Buy Fenobibrate without Prescription Buy Furosemide without Prescription Buy Hyzaar without Prescription Buy Imdur without Prescription Buy Indapamide without Prescription Buy Irbesartan without Prescription Buy Isoptin without Prescription Buy Labetalol without Prescription Buy Lisinopril without Prescription Buy Losartan without Prescription Buy Lotrel without Prescription Buy Metoprolol without Prescription Buy Microzide without Prescription Buy Nebivolol without Prescription Buy Nifedipine without Prescription Buy Olmesartan without Prescription Buy Pentoxifylline without Prescription Buy Perindopril without Prescription Buy Prazosin without Prescription Buy Propranolol without Prescription Buy Quinapril without Prescription Buy Ramipril without Prescription Buy Rosulip-F without Prescription Buy Sotalol without Prescription Buy Spironolactone without Prescription Buy Telmisartan without Prescription Buy Tenormin without Prescription Buy Terazosin Hydrochloride without Prescription Buy Triamterene without Prescription Buy Valsartan without Prescription Buy Vastarel without Prescription Buy Zestoretic without Prescription